Author's Accepted Manuscript

Footwear interventions for foot pain, function, impairment and disability for people with foot and ankle arthritis: A literature review

Mike Frecklington, Nicola Dalbeth, Peter McNair, Peter Gow, Anita Williams, Matthew Carroll, Keith Rome



PII: S0049-0172(17)30590-5

DOI: https://doi.org/10.1016/j.semarthrit.2017.10.01710.1007/s10067-009-131210 0596-010.1002/acr.2058210.1002/acr.2254810.1186/1471-2474-14-27810.1002/acr.2275010.1093/rheumatology/kel23410.1016/j.jclinepi.2010.(1146-2-110.1016/j.clinbiomech.2007.08.00910.1093/rheumatology/kei18610 Reference: YSARH51263

To appear Seminars in Arthritis and Rheumatism in:

Cite this article as: Mike Frecklington, Nicola Dalbeth, Peter McNair, Peter Gow, Anita Williams, Matthew Carroll and Keith Rome, Footwear interventions for foot pain, function, impairment and disability for people with foot and ankle arthritis: A literature review, Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2017.10.017

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Footwear interventions for foot pain, function, impairment and disability for people with foot and ankle arthritis: a literature review

Mike Frecklington^a*, Nicola Dalbeth^{b,c}, Peter McNair^a, Peter Gow^d, Anita Williams^e, Matthew Carroll^a, Keith Rome^a

a Health and Rehabilitation Research Institute, AUT University, Auckland, New Zealand

b The University of Auckland, Auckland, New Zealand

c Auckland District Health Board, Auckland, New Zealand

d Counties-Manukau District Health Board, Auckland, New Zealand

e School of Health Science, University of Salford, Salford, UK

*Corresponding author.

Email address: mike.frecklington@aut.ac.nz

.niversity, Postal address: Health and Rehabilitation Research Institute, AUT University, Private Bag 92006, Auckland 1020, New Zealand

Abstract

Objective: To conduct a literature review on the effectiveness of footwear on foot pain, function, impairment and disability for people with foot and ankle arthritis.

Methods: A search of the electronic databases Scopus, Medline, CINAHL, SportDiscus and the Cochrane Library was undertaken in September 2017. The key inclusion criteria were studies reporting on findings of footwear interventions for people with arthritis with foot pain, function, impairment and/or disability. The Quality Index Tool was used to assess the methodological quality of studies included in the qualitative synthesis. The methodological variation of the included studies was assessed to determine the suitability of meta-analysis and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Between and within group effect sizes were calculated using Cohen's *d*.

Results: 1440 studies were identified for screening with 11 studies included in the review. Mean (range) quality scores were 67% (39%-96%). The majority of studies investigated rheumatoid arthritis (n=7), but also included gout (n=2), and 1st metatarsophalangeal joint osteoarthritis (n=2). Meta-analysis and GRADE assessment were not deemed appropriated based on methodological variation. Footwear interventions included off-the-shelf footwear, therapeutic footwear and therapeutic footwear with foot orthoses. Key footwear characteristics included cushioning and a wide toe box for rheumatoid arthritis; cushioning, midsole stability and a rocker-sole for gout; and a rocker-sole for 1st metatarsophalangeal joint osteoarthritis. Between group effect sizes for outcomes ranged from 0.01-1.26. Footwear interventions were associated with reductions in foot pain, impairment and disability for people with rheumatoid arthritis. Between group differences were more likely to be observed in studies with shorter follow-up periods in people with rheumatoid arthritis (12 weeks). Footwear interventions improved foot pain, function and disability in people with gout and foot pain and function in 1st metatarsophalangeal joint osteoarthritis. Footwear interventions were associated with changes to plantar pressure in people with rheumatoid arthritis, gout and 1st metatarsophalangeal joint osteoarthritis and walking velocity in people with rheumatoid arthritis and gout.

Conclusion: Footwear interventions are associated with reductions in foot pain, impairment and disability in people with rheumatoid arthritis, improvements to foot pain, function and disability in people with gout and improvements to foot pain and function in people with 1st metatarsophalangeal joint osteoarthritis. Footwear interventions have been shown to reduce plantar pressure rheumatoid arthritis, gout and 1st metatarsophalangeal joint osteoarthritis and improve walking velocity in rheumatoid arthritis and gout.

Keywords:

Systematic review, Arthritis, Interventions, Foot, Pain

Introduction

Foot problems are commonly observed by people with foot and ankle arthritis [1, 2]. High levels of foot pain, impairment and disability are also reported in this population [3, 4]. Foot problems in people with arthritis are also associated with reduced function [5] and quality of life [6]. Reduced walking velocity and increased plantar pressure is also observed in people with arthritis [7]. The aim of pharmacological and non-pharmacological management of foot and ankle arthritis is pain reduction, maintenance of function, accommodation of existing deformity and prevention of further deformity. Footwear is routinely used as non-pharmacological intervention [8]. Footwear can include off-the-shelf footwear, therapeutic footwear and therapeutic footwear combined with a foot orthosis. People with arthritis affecting the foot and ankle often use footwear which may contribute to foot pain and associated disability [9] and describe difficulties in finding suitable footwear [10]. Current evidence suggests that footwear may offer benefits for people with foot and ankle arthritis [11-13]. While there are studies examining the effects of footwear, at this time it is difficult to appreciate the strength and consistency of experimental work providing support for the utilisation of footwear in arthritic conditions. Hence, the aim of this review is to evaluate the evidence for the clinical effectiveness of footwear interventions for foot pain, function, impairment and disability in people with arthritis.

Methodology

Identification of studies

The following electronic databases (CINAHL, MEDLINE, Scopus, SPORTDiscus and the Cochrane Library) were searched in September 2017, with no limitations were placed on the publication date. The search strategy comprised of the following keywords: arthritis, rheumatoid arthritis, gout, osteoarthritis, rheumatic disease, psoriatic arthritis, lupus erythematous, ankylosing spondylitis, systemic sclerosis, polymyalgia rheumatica *with* footwear, footwear intervention, foot orthoses, foot orthosis, foot orthotic, insole and shoe (supplementary material table 1). The term 'footwear interventions' encompasses the use of footwear, footwear with orthoses in the management of arthritic conditions.

Inclusion/exclusion criteria

Titles and abstracts were screened by a single reviewer (MF). Full-text articles were obtained from selected abstracts and compared against the following inclusion criteria by a single reviewer (MF). Studies were included if they met the following criteria: being a randomised controlled trial, prospective observational intervention trials or cross-sectional intervention trials; published in English; peer-reviewed publications; participants over the age of 18 years; studies reporting on findings of footwear interventions for people with arthritis with foot pain, function (including temporal-spatial, plantar pressure, kinematic and kinetic data), impairment and/or disability measured as a primary outcome. Studies were excluded if: investigated arthritis not affecting the foot or ankle; case study and case series design; studies reporting findings of interventions where footwear was not been standardised for participants (custom footwear); studies where footwear was used as a control condition for foot orthoses or adapted for three-dimensional marker placement for foot orthosis interventions. Off-the-shelf footwear was defined as commercially available walking and running shoes. Therapeutic footwear was defined as readymade, orthopaedic-style footwear. Citations of retrieved publications were examined to obtain further sources.

Data extraction

A standardised form was used to extract publication details (author(s) and year), study design, participant sample characteristics (age gender, participants entered into study), follow-up period, description of footwear intervention, control/comparator intervention and outcome measures used to assess foot pain, function, impairment and disability were recorded.

Assessment of methodological quality

Methodological quality was independently assessed by two authors (MF and MC) using the Quality Index Tool [14]. The Quality Index Tool comprises of 27 items allowing for the assessment of internal validity, external validity, power, analysis and reporting. Item 27 was adapted to be scored, 0 or 1 based on the reporting of a powered sample size calculation. Total raw scores were converted into a percentage. The tool displays high internal consistency, test-retest reliability and inter-rater reliability [14]. Kappa statistic was used to assess intra-tester agreement between reviewers. All disagreements in scoring were resolved following discussion, with a third reviewer (KR) consulted if consensus could not be reached. The methodological variation of the included studies was assessed to determine the suitability of meta-analysis and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system [15]. Between and within group effect sizes were calculated for the included studies using Cohen's *d*, with effect sizes interpreted as negligible (<0.2), small (\geq 0.2), medium (\geq 0.5) and large (\geq 0.8) [16].

Results

Search results

Following the removal of duplicates, 1440 studies were screened with 1384 records excluded with 56 full-text records obtained (Figure 1). A further 45 records were excluded. Key reasons for the exclusion of studies included the use of custom footwear and the use of footwear as a control condition for 3D gait analysis. A total of 11 studies met the inclusion criteria for assessment. Of the included studies, seven investigated rheumatoid arthritis (RA) [17-19, 13, 20-22], two investigated gout [11, 23], and two investigated first metatarsophalangeal joint osteoarthritis (1MTP OA) [12, 24]. Five studies were randomised clinical trials [18, 19, 13, 21, 12], three studies were prospective observational intervention studies [11, 17, 22] and three studies were laboratory-based intervention studies [20, 23, 24].

Methodological quality of studies

The inter-rater agreement between reviewers showed good agreement (kappa statistic: 0.81). Quality index scores ranged from 39% - 96% (Table 1). Quality assessment of studies highlighted higher bias with respect to blinding of participants and assessors to treatment allocation, blinding of assessors to main outcomes, external validity, adjustment for confounding and reporting adverse events attributed to inventions.

Study characteristics

Study characteristics are displayed in Tables 2-4. A total of 382 participants with arthritis affecting the foot and ankle were reported, with 218 RA, 92 1MTP OA and 72 participants with gout. In the gout and RA studies, the majority of participants had well-established disease duration, but for 1MTP OA the majority had early disease duration. Follow-up period ranged between 8-24 weeks. Meta-analysis and GRADE assessment were not deemed appropriated based on the variation in disease type, interventions and tools used to measure primary outcomes. Negligible to large between group effect sizes were observed for foot pain, function impairment and disability.

Footwear interventions

Footwear interventions included off-the-shelf footwear [20, 11, 23, 12, 24], therapeutic footwear [18, 13, 17, 22, 20] and therapeutic footwear combined with foot orthoses [19, 21].

Off-the-shelf footwear

The use of off-the-shelf footwear was reported in people with RA [20], gout [23, 11] and 1MTP OA [12, 24]. In one study in people with RA, an athletic shoe was used with the footwear characteristic of this shoe being cushioning for forefoot pain [20]. For people with gout a range of walking shoes were used and divided into good footwear characteristics and poor footwear characteristics. Good footwear characteristics included a rocker-sole to facilitate a heel-to-toe gait, a dual-density midsole to provide motion control, heel and forefoot cushioning to improve shock attenuation and a zip to allow for ease of entry and exit of footwear [11, 23]. Poor footwear characteristics included a single density midsole, no cushioning, minimal heel counter stiffness and midsole stability [11, 23]. For people with 1MTP OA, a rocker-sole shoe was used, allowing smoother progression of the body's centre of mass over the stance foot, reducing the amount of 1MTP dorsiflexion required and loading at the forefoot joints [12, 24].

Therapeutic footwear

The use of therapeutic footwear was reported in five studies for people with RA [18, 13, 17, 22, 20]. Footwear characteristics included extra-depth in the forefoot region to accommodate for foot orthoses and forefoot deformity, soft leather upper and smooth lining to offer protection, laces, padded heel counter to improve fit at the heel and a long inside counter to improve rearfoot stability and arch support [18].

Therapeutic footwear combined with foot orthoses

The use of therapeutic footwear with a foot orthosis was reported in two studies for people with RA [19, 21]. Footwear characteristics included a wide and deep toe box was used to accommodate for the foot orthoses. Foot orthoses used in these studies included semi-rigid and soft devices, manufactured as both prefabricated and custom.

Foot pain

Rheumatoid arthritis

Three RCTs [21, 13, 19] and one prospective observational study [22] measured foot pain in people with rheumatoid arthritis. One RCT [13] compared traditional therapeutic footwear to a newer therapeutic footwear designed with patient and practitioner input. After 12 weeks, significant between group improvement was observed for the newer therapeutic footwear group compared to the traditional therapeutic footwear group (d= 0.92-1.26; large effect). Significant within group improvement in foot pain was observed in the newer therapeutic footwear group (d= 1.08-1.24; large effect), with no significant improvement in the traditional therapeutic footwear group (d= 0.18-0.19; negligible effect). Another RCT [19] compared three footwear conditions; extra-depth footwear only, extra-depth footwear with soft foot orthoses and extra-depth footwear with semi-rigid foot orthoses. At 12 weeks, significant between group reductions in MTP pain was reported in the extra-depth footwear with semi-rigid orthoses group compared to the footwear with soft orthoses group (d=0.45; medium effect) and footwear only group (d=0.78; medium effect). There was no significant

within group improvement observed in the footwear with soft orthoses and footwear only groups at 12 weeks. A further RCT [21] compared extra-depth footwear with semi-rigid foot orthoses compared to extra-depth footwear with soft orthoses. After 24 weeks, no significant difference was found between groups (d= 0.46; small effect), however, significant within group improvements in foot pain was observed in the footwear with semi-rigid orthoses group (d=0.56; medium effect) and the footwear with soft orthoses group (d=1.07; large effect). The prospective observational study [22] reported significant within group improvements in foot pain with high-top, rocker-sole footwear after 4 weeks (d=1.45; large effect), however, there was no comparator to this intervention.

Gout

One prospective observational study [11] measured foot pain in people with gout. One group with good footwear characteristics was compared to a group with poor footwear characteristics over an eight-week period. After eight weeks, significant within group improvement in foot pain was observed in the good footwear characteristics group only (d=0.75; medium effect). There was no significant improvement in foot pain in the poor footwear characteristics group (d=0.19; negligible effect).

1MTP OA

One RCT [12] measured foot pain in people with 1MTP OA. Rocker-sole footwear was compared to the participant's own footwear with foot orthoses. After 12 weeks, improvements in foot pain were observed in the rocker-sole footwear group (d=1.25; large effect) and own footwear with foot orthoses group (d=0.95; large effect), however, no significant differences were observed between groups at follow-up (d=0.01; negligible effect).

Patient-reported outcomes

Patient reported outcome measures assessing function, impairment and disability were reported for RA, gout and 1MTP OA.

Rheumatoid arthritis

One RCT [18] reported a significant within group improvement in function in the extra-depth footwear group with no improvement in the control group at eight weeks. The control group of this sample were subsequently provided with extra-depth footwear in a repeated-measures design with significant within group improvements in function at eight weeks (d=0.30; small effect). Another RCT [13] reported significant between group improvement in foot function, functional limitation and disability in the new design therapeutic footwear compared to traditional therapeutic footwear at 12 weeks (d=0.88-1.07; large effect). Significant within group improvement was seen in the new design therapeutic footwear (d=0.92-1.06; large effect) with non-significant within group improvement in the traditional therapeutic footwear group (d=0.04-0.33; negligible-small effect). One RCT [21] comparing therapeutic footwear with soft orthoses and therapeutic footwear with semi-rigid orthoses reported no significant between group differences in activity limitation and disability at 24 weeks (d=0.94; large effect). Non-significant within group improvements in activity limitation and disability was observed in the footwear with semi-rigid orthoses group (d=0.78; medium effect) and the footwear with soft orthoses group (d=1.31; large effect). One prospective observational study [17] reported a significant within group improvement in self-reported walking ability with heatmouldable footwear (unable to calculate effect size). Another prospective observational study [22] reported within group improvements in foot function, activity limitation and disability with rockersole footwear use at four weeks (d=1.03; large effect).

Gout

One prospective observational study [11] measured function, foot-related impairment and disability. Significant improvements in function (d=0.44; small effect) and foot-related disability (d=0.67; medium effect) were observed in the good footwear characteristics group, with no significant differences observed in the poor footwear characteristics group at eight weeks (d=0.14-0.17; negligible effect).

1MTP OA

One RCT [12] measured function. Improvements in foot function were observed in the rocker-sole footwear group (d=0.61; medium effect) and own footwear with foot orthoses group (d=0.58; medium effect), however, no significant differences were observed between groups at follow-up (d=0.04; negligible effect).

Plantar pressure and temporal-spatial parameters

Data for plantar pressure and temporal-spatial parameters was reported for three conditions; RA, gout and 1MTP OA.

Rheumatoid arthritis

One cross-sectional study [20] reported significant reductions in total foot, rearfoot and forefoot peak plantar pressure (PPP) in the running footwear (d=1.84, 1.07, 1.78; large effects) and orthopaedic footwear (d=0.86, 0.82, 0.84; large effects) groups compared to the control group. Significant reductions in total foot (d=1.72, 1.06; large effects) and forefoot pressure (d=1.74, 1.14; large effects) time integrals (PTI) in the running footwear and orthopaedic footwear groups compared to the control group. Significant reductions in rearfoot PTI was observed in the running footwear group compared to the control group (d=0.24; small effect). Significant reductions in PPP and PTI for total foot pressure (d=1.02, 0.87; large effects) and forefoot pressure (d=0.91, 0.84; large effects) in the running footwear group compared to the control group compared to the orthopaedic footwear group. One RCT [18] reported significant within group increases in walking velocity (d=0.31; small effect) and stride length (d=0.30; small effect) following the provision of extra-depth footwear compared to the participant's own shoes after eight weeks. Another RCT [19] reported no within group or between group improvements during overground walking, stair climbing or 50 foot walk time with extra-depth footwear only, extra-depth footwear with soft orthoses and extra-depth footwear with semi-rigid orthoses after 12 weeks (d=0-0.16; negligible effect).

Gout

One cross-sectional study [23] compared good footwear characteristics to poor footwear characteristics to the participant's own footwear. Significant reductions in PPP and PTI at the heel and 5MTP with increases in midfoot pressure was observed in the good footwear characteristics group compared to the poor footwear characteristics footwear group (d=0.02-0.70; negligible-medium effect). Significant within group reductions in PPP at 3MTP and 5MTP, reductions in PTI at 3MTP, 5MTP and heel with increases in midfoot PTI was observed in the good footwear characteristics group compared to their own footwear (d=0.03-1.11; negligible-large effect).

Significant within group increases in PPP at the heel and lesser toes, reductions at 3MTP and reductions in midfoot PTI was observed in the poor footwear characteristics group compared to their own footwear (d=0.02-0.44; negligible-small effect). Significant within group increases in walking velocity, step length and stride length in both the good and poor footwear characteristics groups compared to the participant's own footwear (d=0.16-0.53; negligible-medium effect), however, no between group differences were observed (d=0.29; small effect).

1MTP OA

One cross-sectional study [24] reported significant within group reductions in PPP were observed at 1MTP (d=0.31; small effect), 2-5MTP (d=0.91; large effect) and heel (d=0.90; large effect) in the rocker-sole footwear group compared to the participant's own footwear. Significant reductions in PPP at lesser toes (d=0.35; small effect), 2-5MTP (d=1.12; large effect) and midfoot (d=0.72; medium effect) was observed between the footwear intervention group compared to the own footwear with orthoses group. A significant reduction in stance phase percentage (d=0.51; medium effect) in the rocker-sole footwear group compared to the own footwear with orthoses group. Significant within-group reductions for cadence (d=0.25; small effect) and stance phase percentage (d=0.43; small effect) were observed in the rocker-sole footwear group compared to the participant's own footwear.

Discussion

The aim of this systematic review was to identify and evaluate the evidence for the clinical effectiveness of footwear interventions for foot pain, function, impairment and disability in people with arthritis. Despite the broad search strategy, the search only identified studies investigating RA, gout and 1MTP OA. The findings of the review support that footwear is associated with improvements to foot pain, function, impairment and disability in people with RA. There is evidence to suggest that footwear is associated with improvements to foot pain, function and disability in people with gout and improvements to foot pain and function in people with 1MTP OA. A greater body of evidence exists for RA compared to gout and OA, and there are no studies of footwear interventions for other forms of arthritis.

Within and between group effect sizes for foot pain indicate that footwear interventions are likely to result in improvements to foot pain in people with arthritis. However, for people with rheumatoid arthritis there was conflicting evidence between studies as to which type of intervention was preferable. Between group findings indicated the majority of studies in favour of therapeutic footwear with a semi-rigid insole compared to therapeutic footwear with a soft insole on foot pain, however, one study favoured therapeutic footwear with a soft insole compared to a semi-rigid insole.

There was considerable variation in the methodology with respect to the footwear interventions and measures used to assess both primary and secondary outcomes. Of the included studies, footwear interventions included footwear only and footwear with orthoses conditions. It is difficult to isolate the individual treatment effect of footwear and foot orthoses when prescribed individually or as co-interventions. It is also difficult to ascertain if the observed changes are related to 'the footwear' or specific characteristics of the footwear. There is currently no universally accepted standard for the measurement of foot pain and self-reported foot pain intensity is the most frequently used research tool to measure foot pain [25]. Instruments include visual analogue scales (VAS), numeric rating

scales and verbal category/Likert scale. The complexity of arthritic conditions may advocate the use of multiple tools to capture the spectrum of foot pain across a particular condition.

In the RCTs investigating RA, differences between groups was observed in studies with a shorter follow-up period (from 4 to 12 weeks) compared to studies with a longer follow-up period (24 weeks). The lack of a control group in the observational studies for people with RA was also a limitation. It is difficult to discuss the influence of follow-up periods for gout and 1MTP OA as there was only one longitudinal study for each condition. The description of footwear interventions ranged from the use of footwear assessment scales, listing desirable footwear characteristics or simply stating the type of footwear. There was also inconsistency in the observed changes to outcomes in the control groups in the RA population. Such variance in the description of footwear and findings makes it difficult to determine if changes to the outcomes are be attributed to 'footwear' or specific footwear characteristics.

Footwear was associated with reductions in plantar pressure in people with RA, gout and 1 MTP OA. The studies included which investigated plantar pressure all employed a cross-sectional design, so it is unclear whether these changes are maintained over time or are associated with improvements to patient reported outcomes. Footwear was also associated with changes to walking velocity and stance time. Significant reductions in walking velocity have been found in people with arthritis [7]. Reduced walking velocity and increased stance time are indicative of foot related-impairment and disability [26]. A limitation of these findings is that their relationship to other parameters such as inshoe kinematics and kinetics is unknown.

When considering footwear for people with RA, key footwear characteristics associated with improvements to patient reported outcomes included extra-depth footwear and cushioning. Adequate toe box volume allows for the accommodation of forefoot deformity and foot orthoses. Foot pain associated with forefoot deformity [26] and increased forefoot plantar pressure have been reported people with RA [27]. Footwear with cushioned midsoles can significantly reduce forefoot plantar pressure in people with RA [20]. The mean disease duration in the included studies is indicative of participants with established RA. People with early onset RA may present with different footwear needs.

Footwear characteristics which may be associated with improvements to foot pain and disability include cushioning and support for people with gout [11]. These benefits may be related to changes in plantar pressure and temporal-spatial parameters [23]. Footwear with an absence of cushioning, minimal heel counter and midsole stability were not associated with improvements to foot pain in people with gout [11]. Footwear with poor cushioning and support is common in people with gout and is associated with higher levels of foot-related impairment and disability [9]. Difficulties finding footwear which fits appropriately, accommodates existing deformity and is suitable for activities of daily living has been identified by people with gout [28-30]. Further investigation into these domains may help to improve understanding regarding footwear habits of people with gout.

For people with 1MTP OA, the rocker-sole characteristic of the footwear was found to reduce loading at the 1MTP and subsequent improvement in patient reported outcomes. These reductions may be attributed to reductions in 1-5MTP plantar pressure, cadence and stance time percentage observed with the rocker-sole footwear compared to participant's own footwear [24]. Biomechanical changes have been reported with rocker-sole footwear in both asymptomatic and symptomatic populations, however, it is difficult to determine if these changes are associated with improved patient-reported outcomes [31].

This review is not without limitations. Pooling of data was not possible due to the methodological inconsistency between the included studies, thus recommendations regarding the most appropriate intervention cannot be made. The search strategy did not include unpublished literature including theses and conference proceedings. Differences in the reporting of footwear characteristics made it difficult to draw conclusions regarding the influence of specific design features on patient-reported outcomes and biomechanical variables. Not all types of footwear have been tested in clinical studies, and it is unclear whether findings can be generalised to other types of footwear which may deliver different biomechanical effects. As much of the data presented comes from cross-sectional studies, the long-term effects of footwear on gait parameters remains unclear.

Future work needs to explore the foot-related problems and footwear needs of people with other arthritic conditions. Improved understanding of these conditions may help to determine the role of footwear interventions in the management of these populations. The majority of the studies included in this review were for RA with only one RCT with a follow-up period beyond 12 weeks. Longitudinal prospective studies and randomised clinical trials may help to determine the clinical effectiveness of footwear. Further prospective studies may help to determine if changes to gait parameters associated with footwear are preserved and associated with improvements to patient reported outcomes.

Conclusion

Footwear interventions are associated with reductions in foot pain, impairment and disability in people with rheumatoid arthritis, improvements to foot pain, function and disability in people with gout and improvements to foot pain and function in people with 1st metatarsophalangeal joint osteoarthritis. Footwear interventions have been shown to reduce plantar pressure rheumatoid arthritis, gout and 1st metatarsophalangeal joint osteoarthritis and improve walking velocity in rheumatoid arthritis and gout.

Acknowledgements

None.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

N Dalbeth has received personal fees from Takeda, grants and personal fees from AstraZeneca/Ardea Biosciences, personal fees from Abbvie, personal fees from Cymabay, personal fees from Horizon, grants from Amgen outside the submitted work. The authors declare that they have no other conflicts of interest regarding the content of this article.

Accepted manuscript

References

- 1. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Cheek L, et al. Foot pain in rheumatoid arthritis prevalence, risk factors and management: An epidemiological study. Clin Rheumatol 2010;29:255-71. DOI: 10.1007/s10067-009-1312.
- 2. Roddy E, Muller S, Rome K, Chandratre P, Hider SL, Richardson J, et al. Foot problems in people with gout in primary care: baseline findings from a prospective cohort study. J Foot Ankle Res 2015;8:31. DOI: 10.1186/s13047-015-0090-9.
- 3. Rome K, Frecklington M, McNair P, Gow P, Dalbeth N. Foot pain, impariment, and disability in patients with acute gout flares: a prospective observational study. Arthritis Care Res 2012;64:384–8. DOI: 10.1002/acr.20670.
- 4. Roddy E, Thomas MJ, Marshall M, Rathod T, Myers H, Menz HB, et al. The population prevalence of symptomatic radiographic foot osteoarthritis in community-dwelling older adults: cross-sectional findings from the clinical assessment study of the foot. Ann Rheum Dis 2015;74:156-63. DOI: 10.1136/annrheumdis-2013-203804.
- 5. Stewart S, Morpeth T, Dalbeth N, Vandal AC, Carroll M, Davidtz L, et al. Foot-related pain and disability and spatiotemporal parameters of gait during self-selected and fast walking speeds in people with gout: A two-arm cross sectional study. Gait Posture 2016;44:18-22. DOI: 10.1016/j.gaitpost.2015.11.004.
- 6. Wickman AM, Pinzur MS, Kadanoff R, Juknelis D. Health-related quality of life for patients with rheumatoid arthritis foot involvement. Foot Ankle Int 2004;25:19-26. DOI: 10.1177/107110070402500105.
- Carroll M, Parmar P, Dalbeth N, Boocock M, Rome K. Gait characteristics associated with the foot and ankle in inflammatory arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 2015;16:134. DOI: 10.1186/s12891-015-0596-0.
- 8. Rome K, Erikson K, Ng A, Gow PJ, Sahid H, Williams AE. A new podiatry service for patients with arthritis. N Z Med J 2013;126:70-7.
- 9. Rome K, Frecklington M, McNair P, Gow P, Dalbeth N. Footwear characteristics and factors influencing footwear choice in patients with gout. Arthritis Care Res 2011;63:1599–1604. DOI: 10.1002/acr.20582.
- 10. Hendry GJ, Brenton-Rule A, Barr G, Rome K. Footwear experiences of people with chronic musculoskeletal diseases. Arthritis Care Res 2015;67:1164-72. DOI: 10.1002/acr.22548.
- 11. Rome K, Stewart S, Vandal AC, Gow P, McNair P, Dalbeth N. The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study. BMC Musculoskelet Disord 2013;14:278. DOI: 10.1186/1471-2474-14-278.
- 12. Menz HB, Auhl M, Tan JM, Levinger P, Roddy E, Munteanu SE. Effectiveness of Foot Orthoses Versus Rocker-Sole Footwear for First Metatarsophalangeal Joint Osteoarthritis: Randomized Trial. Arthritis Care Res 2016;68:581-9. DOI: 10.1002/acr.22750.
- 13. Williams AE, Rome K, Nester CJ. A clinical trial of specialist footwear for patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46:302-7. DOI: 10.1093/rheumatology/kel234.
- 14. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84.
- 15. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Clin Epidemiol 2011;64:383-94. DOI: 10.1016/j.jclinepi.2010.04.026.
- 16. Cohen J. A power primer. Psychological Bulletin 1992;112:155-9.
- 17. Moncur C, Ward JR. Heat-moldable shoes for management of forefoot problems in rheumatoid arthritis. Arthritis Care Res 1990;3:222-6.
- 18. Fransen M, Edmonds J. Off-the-shelf orthopedic footwear for people with rheumatoid arthritis. Arthritis Care Res 1997;10:250-6.

- 19. Chalmers AC, Busby C, Goyert J, Porter B, Schulzer M. Metatarsalgia and rheumatoid arthritis

 A randomized, single blind, sequential trial comparing 2 types of foot orthoses and
 supportive shoes. J Rheumatol 2000;27:1643-7.
- 20. Hennessy K, Burns J, Penkala S. Reducing plantar pressure in rheumatoid arthritis: a comparison of running versus off-the-shelf orthopaedic footwear. Clin Biomech 2007;22:917-23. DOI: DOI: 10.1016/j.clinbiomech.2007.04.011.
- 21. Cho NS, Hwang JH, Chang HJ, Koh EM, Park HS. Randomized controlled trial for clinical effects of varying types of insoles combined with specialized shoes in patients with rheumatoid arthritis of the foot. Clin Rehabil 2009;23:512-21. DOI: 10.1177/0269215508101737.
- 22. Bagherzadeh Cham M, Ghasemi MS, Forogh B, Sanjari MA, Zabihi Yeganeh M, Eshraghi A. Effect of rocker shoes on pain, disability and activity limitation in patients with rheumatoid arthritis. Prosthet Orthot Int 2014;38:310-5. DOI: 10.1177/0309364613498537.
- 23. Stewart S, Dalbeth N, McNair P, Parmar P, Gow P, Rome K. The effect of good and poor walking shoe characteristics on plantar pressure and gait in people with gout. Clin Biomech 2014;29:1158-63. DOI: 10.1016/j.clinbiomech.2014.09.009.
- 24. Menz HB, Auhl M, Tan JM, Levinger P, Roddy E, Munteanu SE. Biomechanical Effects of Prefabricated Foot Orthoses and Rocker-Sole Footwear in Individuals with First Metatarsophalangeal Joint Osteoarthritis. Arthritis Care Res 2016;68:603-11. DOI: 10.1002/acr.22743.
- 25. Hawke F, Burns J. Understanding the nature and mechanism of foot pain. J Foot Ankle Res 2009;2:1. DOI: 10.1186/1757-1146-2-1.
- 26. Turner DE, Helliwell PS, Siegel KL, Woodburn J. Biomechanics of the foot in rheumatoid arthritis: identifying abnormal function and the factors associated with localised disease 'impact'. Clin Biomech 2008;23:93-100. DOI: 10.1016/j.clinbiomech.2007.08.009.
- 27. van der Leeden M, Steultjens M, Dekker JH, Prins AP, Dekker J. Forefoot joint damage, pain and disability in rheumatoid arthritis patients with foot complaints: the role of plantar pressure and gait characteristics. Rheumatology (Oxford) 2006;45:465-9. DOI: 10.1093/rheumatology/kei186.
- 28. Aati O, Taylor WJ, Horne A, Dalbeth N. Toward development of a tophus impact questionnaire: a qualitative study exploring the experience of people with tophaceous gout. J Clin Rheumatol 2014;20:251-5. DOI: 10.1097/RHU.00000000000127.
- 29. Martini N, Bryant L, Te Karu L, Aho L, Chan R, Miao J, et al. Living with gout in New Zealand: an exploratory study into people's knowledge about the disease and its treatment. J Clin Rheumatol 2012;18:125-9. DOI: 10.1097/RHU.0b013e31824e1f6f.
- 30. Singh JA. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol 2014;20:172-4. DOI: 10.1097/RHU.0000000000091.
- Tan JM, Auhl M, Menz HB, Levinger P, Munteanu SE. The effect of Masai Barefoot Technology (MBT) footwear on lower limb biomechanics: A systematic review. Gait Posture 2016;43:76-86. DOI: 10.1016/j.gaitpost.2015.10.017.

Tables/figures

In-text figures and tables:

Figure 1: PRISMA flow diagram of search strategy

Table 1: Quality Index scoring of included studies

 Table 2: Description of randomised clinical trials

Table 3: Description of included prospective observational intervention studies

Table 4: Description of included lab-based intervention studies

Supplementary material:

Table 1: Search strategy

Accepted manuscript

Figure 1

PRISMA flow diagram of search strategy




Table 1

Quality assessment scores of included studies

. ,										1	studie	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2
	1	2	3	4	5	6	7	8	9	0	11	1 2	3	4	т 5	6	1 7	8	9	0	2	2	2	4	2 5	2 6	2 7
Monc ur & Ward, 1990	1	1	1	1	0	1	0	1	1	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0	1	0
[17] Frans																											
en & Edmo nds, 1997 [18]	1	1	1	1	1	1	1	0	0	1	0	0	0	0	0	1	1	0	1	1	1	0	1	0	0	1	1
Chalm ers et al. 2000 [19]	1	1	1	1	1	1	1	1	1	1	0	0	1	0	1	1	1	1	1	1	1	1	1	0	0	1	1
Willia ms et al. 2007 [13]	1	1	1	1	1	1	1	1	1	1	0	0	1	1	0	1	1	1	0	1	1	0	1	1	0	0	1
Henn essy et al. 2007 [20]	1	1	1	1	1	1	1	0	n a	1	0	0	1	1	0	1	n a	1	n a	1	1	1	1	1	0	n a	1
Cho et al. 2009 [21]	1	1	1	1	1	1	1	0		1	0	0	1	0	0	0	1	1	0	1	1	1	1	0	0	0	1
Rome et al. 2013 [11]	1	1	1	1	1	1	1	1	1	1	0	1	1	1	0	1	1	1	1	1	1	0	1	1	1	1	1
Baghe rzade h Cham et al. 2014 [22]	1	1	1	1	1	1	1	0	1	1	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	1	0
Stewa rt et	1	1	1	1	1	1	1	0	n a	1	0	1	1	1	0	1	n a	1	n a	1	1	0	1	1	1	n a	0

al.																				
2014																				
[23]																				
Menz																				
et al.	1 1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1
2016 1 1 1 2 1	1 1	T	1	1	1	1	0	1	T	1	1	1	1	T	1	1	1	1	T	1
[12]																				
Menz																				
et al. 1 1 1 1 2 1	1 0	n	1	1	1	1	0	0	1	n	1	n	1	1	1	1	1	1	n	0
2016		а	Т	Т	1	Т	0	U	т	а	Т	а	Т	Т	1	1	T	Ŧ	а	0
[24]																				
1 Study objectives clearly	descr	bed	?	1	5 B	lindi	ing	of a	sses	sor	s m	eası	urin	g m	ain	out	com	es?		
2 Main outcome measure		ribe	ed in	1	.6 R	esul	ts b	ase	d or	n da	ta d	red	ging	g ma	ade	clea	ar?			
introduction and methods	?			1	7 A	djus	tme	ent	for o	diffe	eren	t le	ngtł	ns o	f fo	llow	'-up	?		
3 Patient characteristics cl	early			1	.8 St	atis	tica	l te	sts f	or r	nair	n ou	tco	mes	ар	prop	oriat	te?		
described?				1	9 C	omp	oliar	ice	with	n int	erv	enti	on i	relia	able	?				
		d?				lain														-
	roduction and methods? Patient characteristics clearly scribed? nterventions clearly described? Distribution of confounders scribed? Main study findings clearly describe															· ·	opu			
described?	Patient characteristics clearly scribed? nterventions clearly described? Distribution of confounders scribed? Main study findings clearly describe Estimates of random variability in da							d co	ntro	olsi	ecr	uite	d o	ver	the	sam	ne p	erio	d of	f
	scribed? nterventions clearly described? Distribution of confounders scribed? Aain study findings clearly describe																_			
		y in	dat			atie									-		•			
						and						ed f	rom	n pa	tien	its a	nd a	asse	sso	rs
•						afte										2				
9 Characteristics of patien	ts los	t to				deq									-	-			~	
follow-up described?						osse					o foi	low	-up	tak	e in	to a	ICCO	unt	ť.	
10 Confidence intervals ar	nd/or	асти	iai P	2	.7 P	owe	r ca	ICUI	atio	n?										
values reported?																				
11 Subjects asked to partie representative of entire per	•		c																	
	•																			
12 Subjects who agreed to representative of entire p																				
13 Staff and facilities repr																				
treatment patients receive		ative	. 01																	
14 Blinding of patients to		enti	ons	2																
Table 2	inter v	Circl	5115	•																

Characteristics of included randomised clinical trials

Author	Nos (% Femal e)	Sample characteris tics Mean (SD)	Follo w-up (week s)	Intervention	Control	Outcom e measur es	Findings	Quali ty score
Franse	15 RA	Interventio	8	Extra-depth	Own	Primary	Between	54%
n &	(80%)	n group		footwear	footwear	outcom	group	
Edmon		Age: 59		(P.W. Minor		e Not	measures	
ds,	15	(14)		& Son Inc.)		stated	Not	
1997	Contr	Disease		·····			reported.	

			ACCE	PTED MAN	USCRIPT			
[18]	ols	duration:		Long inside		Outcom	Within	
	(67%)	16 (10)		counter (rear		es	group	
		, <i>,</i>		stability and		assesse	measures	
		Control		arch		d	Significant	
		group		support),		Lower	reduction	
		Age: 60 (9)		foam padded		limb	in lower	
		Disease		heel counter		walk	limb walk	
		duration:		(leather		pain,	pain	
		15 (12)		lining), soft		lower	(p=0.001),	
				leather		limb	lower limb	
				upper, extra		stair	stair pain	
				depth		pain,	(p=0.001),	
				(orthoses		lower	HAQ	
				accommodat		limb	scores	
				ion)		NWB	(p=0.04)	
						pain	with a	
						(VAS)	significant	
						Functio	increase	
						n (HAQ)	in pain-	
						Pain-	free walk	
						free	time	
						walk	(p=0.001)	
					G	time	for	
						(minute	interventi	
						s)	on group	
						Tempor	at follow-	
						al-	up. No	
						spatial	significant	
						(normal	difference	
						and fast	s found in	
						walking	the	
						velocity	control	
						,	group at	
						cadenc	follow-up.	
						e, stride		
						length)	Significant	
		CCC					improvem	
		6					ent	
							(p<0.05)	
							in normal	
							and fast	
							walking	
							velocity	
							and stride	
							length for interventi	
							on group at follow-	
							up. No	
							significant	
							observed	
	L						UDJCI VEU	

			ACCE	PTED MAN	USCRIPT	•		
							in control group at follow-up.	
Chalme rs et al. 2000 [19]	28 RA (75%)	Total sample Age: 60 (10) Disease duration: 15 (9)	12	Extra-depth footwear (P.W. Minor or Drew Co) Firm heel counter, heel height 1.5- 2.0 cm, instep lacing, wide deep toe box, thick composite sole Extra-depth footwear + soft orthoses Firm heel counter, heel height 1.5- 2.0 cm, instep lacing, wide deep toe box, thick composite sole Soft orthoses; 6mm Plastazote with medium		Primary outcom e MTP pain (VAS) Outcom es assesse d Lower extremi ty functio n (RB, TADL, 50ft walk time)	Between group measures Significant improvem ent in MTP pain scores (p=0.006) for footwear and semi- rigid orthoses group, compared to footwear and soft orthoses group and footwear and soft orthoses group and footwear alone. No significant difference s in RB, TADL and 50ft walk time between groups.	79%

			ACCEI	PTED MAN	USCRIPT			
				density 6mm			Within	
				Plastazote			group	
				metatarsal			measures	
				lifts			Significant	
				Extra-depth			improvem	
				footwear +			ent in	
				semi-rigid			MTP pain	
				orthoses			scores	
				Semi-rigid			(p=0.0004	
				orthoses;) for	
				NWB cast,			footwear	
				3mm			with semi-	
				Subortholen,			rigid	
				RF and FF			orthoses	
				Nickleplast			at follow-	
				posting, FF			up. No	
				3mm PPT			significant	
				foam, full			difference	
				length			s in MTP	
				leather top			pain with	
				cover			footwear	
							and	
							Plastazote	
							and	
							footwear	
							only	
							groups at	
							follow-up.	
							No	
							significant	
							difference	
							s in RB,	
							TADL, and	
							50ft walk	
			~				time and	
							joint	
							count	
							within	
		-					groups.	
William	40 RA	Total	12	New	Traditiona	Primary	Between	71%
s et al.	(73%)	sample		therapeutic	1	outcom	group	
2007	40	Age: not		footwear	therapeuti	es	measures	
[13]	40 Country	reported		Front of	C	Foot	Significant	
	Contr	Disease		shoe, heel	footwear	pain,	improvem	
	ols	duration:		and sole	Soft, flat	disabilit	ent in FFI	
	(53%)	17 (10)		unit, leather	6mm	у,	foot pain	
				and lining,	Plastazote,	activity	(p=0.02),	
				ease of	3mm	limitati	disability	
				don/doff,	Poron	on (FFI)	(p=0.01),	
						Foot	limitation	

			ACCE	PTED MAN	USCRIPT			
Cho et al. 2009 [21]	22 RA (100%) 20 Contr ols (100%)	Interventio n group Age: 49 (12) Disease duration: 8 (6) Control group Age: 49 (12) Disease duration: 7 (7)	24	Extra-depth shoes + custom orthoses Wide toe box, cushioned heel, forefoot rocker Custom orthoses: medial arch support, medial heel post, metatarsal pad	Extra- depth shoes + prefabrica ted insoles Wide toe box, cushioned heel, forefoot rocker Prefabrica ted insole; 6mm Plastazote	Primary outcom es Foot pain (VAS) Foot pain, disabilit y, activity limitati on (FFI)	ent in FHSQ foot pain (p=0.00), foot function (p=0.00) and physical activity scores (p=0.02) for interventi on group at follow- up. No significant within group improvem ent in the control group at follow-up. Between group measures No significant difference s in foot pain and FFI total scores between interventi on and control group at follow-up. Externe s in foot pain and FFI total scores between interventi on and control group at follow-up. Within group measures Significant difference s in foot pain and control group at follow-up.	61%

			ACCE	PTED MAN	USCRIPT			
et al. 2 2016 ([12] (46 1MTPJ OA (61%) 52 Contr ols (44%)	Interventio n group Age: 57 (11) Median Disease duration: 2 Control group Age: 57(11) Median Disease duration: 3	12 12	PTED MAN Rocker-sole footwear (Masai Barefoot Technology (MBT) Mahuta/Mat wa) Rounded sole, soft cushioned heel	Own footwear + orthoses (Vasyli Customs) Full length, cut out under 1 st metatarsal , varus wedge (FPI >7)	Primary outcom e Foot pain (FHSQ) Outcom es assesse d Functio n (FHSQ) Foot pain, stiffnes S,	in interventi on and control groups at follow-up. Between group measures No significant difference s in foot pain, function, stiffness, difficulty, activity limitation, social issues, MTP pain and MTP stiffness between	96%
		duration: 3			nu	Foot pain, stiffnes	issues, MTP pain and MTP	
				3 10	0	activity limitati on, social issues	follow-up. Within group measures Not	
		CO	0			(FFI-R SF) 1MTP walk pain, 1MTP	reported.	
NW/P: pop	Weight	Garing VAS:	/icual An	alogue Scale, HA		rest pain, 1MTP stiffnes s (VAS)	Juestionnaira	

NWB: non-weightbearing, VAS: Visual Analogue Scale, HAQ: Health Assessment Questionnaire, MTP: metatarsophalangeal joint, RB: Robinson Bashall Functional Assessment, TADL: Toronto Activities of Daily Living Measure, FFI: Foot Function Index, FHSQ: Foot Health Status Questionnaire, FFI-R SF: Foot Function Index - Revised (Short Form), SF: Short Form

Table 3

Characteristics of included prospective observational studies

Author	Nos (% Femal e)	Sample characteris tics Mean (SD)	Follo w-up (week s)	Interventio n	Contro I	Outcome measure s	Findings	Quali ty score
Moncur & Ward 1990 [17]	25 RA (100%)	Age: 57 (not reported) Disease duration: not reported	12	Heat- mouldable shoes (Thermold, P. W. Minor Extra Depth Shoe Co) Extra depth, extra forefoot width, mouldable Plastomold lining, pillow top, leather upper, heat mouldable	No control	Primary outcome Not stated Outcome s assessed Walking ability (1- 10 Likert scale)	Between group measures Not assessed. Within group measures Significant improveme nt in walking ability (p<0.01) at follow-up.	39%
Rome et al. 2013 [11]	36 Gout (8%)	Age: 57 (13) duration: 15 (11)	8	Good footwear characteris tics (ASICS Cardio Zip) Leather upper, rubber sole, dual density midsole, rigid heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear	Own footwe ar	Primary outcome Foot pain (VAS) Outcome s assessed Function (HAQ-II) General pain (VAS) Lower limb function (LLTQ) Impairm ent and disability (LFIS)	Between group measures Not assessed. Within group measures Significant improveme nt in foot pain (p=0.002), general pain (p=0.002), general pain (p=0.001), HAQ-II (p=0.002) and LFIS impairmen t subscale (p=0.004)	86%

ACCEPT	ED MANUSCRI	РΤ		
	characteris		observed	
	tics		in good	
	(Dunlop		footwear	
	Asteroid)		characteris	
	Synthetic		tics group	
	upper,		at follow-	
	rubber		up.	
	sole, single			
	density		No	
	midsole,		significant	
	minimal		improveme	
	heel		nt in poor	
	counter		footwear	
	stiffness,		characteris	
	minimal		tics group	
	midfoot		at follow-	
	sole		up.	
	stability, no			
	cushioning			
	(Dunlop			
	Apollo)			
	Synthetic			
	upper,			
	synthetic			
	sole, single			
	density			
	midsole,			
	minimal heel			
	counter stiffness,			
	minimal			
	midfoot			
	sole			
	stability,			
	no			
ACCEQ.	cushioning			
	(Helix			
	Viper)			
	Synthetic			
	upper,			
	Phylon			
	sole, single			
	density			
	midsole,			
	moderate			
	heel			
	counter			
	stiffness,			
	minimal			
	midfoot			

		AC	CEPI	ED MANU	JSCRIF			
				sole stability, heel and forefoot cushioning				
Bagherza deh Cham et al. 2014 [22]	18 RA (100%)	Age: 47 (8) Disease duration: 8 (7)	4	Rocker- soled footwear High-top, wide toe box, Velcro, heel-toe rocker	No control	Primary outcome Not stated Outcome s assessed Foot pain, disability , activity limitatio n (FFI)	Between group measures Not assessed. Within group measures Significant improveme nt in FFI pain (p=0.001), disability (p=0.044), activity limitation (p=0.04) and total (p=0.001) scores at follow-up.	50%

Questionnaire, LFIS: Leeds Foot Impact Scale, FFI: Foot Function index

Accel

Table 4

Characteristics of included lab-based intervention studies

Author	Nos (% Female)	Sample characteristi cs Mean (SD)	Interventions	Control	Outcom e measure s	Findings	Qualit y score
Henness y et al. 2007 [20]	20 RA (80%)	Mean (SD) Age: 60 (11) Disease duration: not reported	Running shoe (Brooks Glycerin 3, Texas Peak Pty Ltd.) Commercially available, 'premium' cushioned running shoe Orthopaedic footwear (P.W. Minor and Son) Extra-depth, cushioning	Control (Dunlop volley) Sock liner removed, thin flexible sole	s Primary outcome Plantar pressure (PPP, PTI)	Between group measures PPP significantl y reduced at forefoot, rearfoot and total foot in running shoe (p<0.001) and orthopaed ic shoe (p<0.001) compared to control. PTI significantl y reduced at forefoot (p<0.001), rearfoot (p<0.001), rearfoot (p<0.001), rearfoot (p<0.001), rearfoot (p<0.001), rearfoot (p<0.001), with the running shoe compared to the control. PTI significantl y reduced at forefoot	64%
						at forefoot (p<0.001) and total	

		AC	CEPTED M	ANUSCRIP	T		
						(p<0.001) with the orthopaed ic shoe compared to the control.	
						Within group measures Not assessed.	
Stewart et al.	21 Gout	Good footwear	Good footwear	Between	Primary outcome	Between group	64%
2014	(5%)	group	characteristics	group Good	Not	measures	
[23]		Age: 57(13)	(ASICS Cardio	footwear	stated	Significant	
	15	Disease	Zip)	characteristi		decrease	
	Gout	duration: 13	Leather upper,	cs and poor	Outcom	in PPP at	
	(13%)	(8)	rubber sole,	footwear	es assessed	the medial heel	
		Poor	dual density	characteristi	Plantar	(p=0.000)	
			midcolo rigid				
		footwear	midsole, rigid heel counter,	CS	pressure	and 5MTP	
		footwear group	heel counter, moderate		pressure (PPP,	and 5MTP (p=0.000)	
		footwear group Age: 58 (14)	heel counter, moderate midfoot sole	Within	pressure (PPP, PTI)	and 5MTP (p=0.000) in the	
		footwear group Age: 58 (14) Disease	heel counter, moderate midfoot sole stability, heel	Within group	pressure (PPP, PTI) Tempora	and 5MTP (p=0.000) in the good	
	P	footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot	Within	pressure (PPP, PTI) Tempora I-spatial	and 5MTP (p=0.000) in the good footwear	
	P	footwear group Age: 58 (14) Disease	heel counter, moderate midfoot sole stability, heel	Within group Participant's	pressure (PPP, PTI) Tempora I-spatial (walking velocity,	and 5MTP (p=0.000) in the good footwear group compared	
	P	footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step	and 5MTP (p=0.000) in the good footwear group compared to the	
	P	footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear characteristics	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step length,	and 5MTP (p=0.000) in the good footwear group compared to the poor	
	P	footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear characteristics (Dunlop	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step length, stride	and 5MTP (p=0.000) in the good footwear group compared to the poor footwear	
		footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear characteristics (Dunlop Asteroid)	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step length,	and 5MTP (p=0.000) in the good footwear group compared to the poor	
		footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear characteristics (Dunlop Asteroid) Synthetic	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step length, stride length,	and 5MTP (p=0.000) in the good footwear group compared to the poor footwear	
		footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear characteristics (Dunlop Asteroid)	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step length, stride length,	and 5MTP (p=0.000) in the good footwear group compared to the poor footwear group. Significant decrease	
		footwear group Age: 58 (14) Disease duration: 18	heel counter, moderate midfoot sole stability, heel and forefoot cushioning Poor footwear characteristics (Dunlop Asteroid) Synthetic upper, rubber	Within group Participant's own	pressure (PPP, PTI) Tempora I-spatial (walking velocity, step length, stride length,	and 5MTP (p=0.000) in the good footwear group compared to the poor footwear group. Significant	

AC	CEPTED M	ANUSCRIP	T		
	minimal heel			lateral	
	counter			heel	
	stiffness,			(p=0.001)	
	minimal			and 5MTP	
	midfoot sole			(p=0.005)	
	stability, no			and a	
	cushioning			significant	
	(Dunlop			increase in	
	Apollo)			PTI at the	
	Synthetic			midfoot	
	upper,			(p=0.000)	
	synthetic sole,			in the	
	single density			good	
	midsole,			footwear	
	minimal heel			group	
	counter			compared	
	stiffness,			to the	
	minimal			poor	
	midfoot sole		٠	footwear	
	stability, no			group.	
	cushioning			Broup.	
	(Helix Viper)			No	
	Synthetic		6	significant	
	upper, Phylon			difference	
	sole, single			s in	
	density			velocity,	
	midsole,			step	
	moderate heel			length,	
	counter			stride	
	stiffness,	~		length or	
	minimal			cadence	
	midfoot sole			between	
	stability, heel			groups.	
	and forefoot			Within	
	cushioning			group	
				measures	
				Significant	
				reduction	
				in PPP at	
				3MTP	
				(p=0.003)	
				and 5MTP	
				(p=0.001).	
				Decreased	
				PTI at heel	
				(p=0.000),	
				(p=0.000), 3MTP	
				(p=0.000)	
				and 5MTP	
				(p=0.005)	

AC	CEPTED M	ANUSCRIP	T		
				increased PTI at midfoot (p=0.000) with good footwear group compared to control. Significant reduction in PPP at 3MTP (p=0.004) and increased PPP at heel (p=0.000) and lesser digits (p=0.003). Decreased PTI at midfoot (p=0.003) in poor footwear group compared to control. Significant increase in velocity (p=0.000), step length (p=0.000) and stride length (p=0.000) in both interventi on groups compared to control.	

Menz et	46	Rocker-sole	Rocker-sole	Between		Between	71%
al. 2016	40 1MTPJ				Primary outcome		/1/0
	OA	group	footwear	group		group	
[24]		Age: 57 (11) Median	(MBT	Participant's	Not	measures	
	(61%)	Disease	Mahuta/Matw	own footwear +	stated	Significant reduction	
	52		a)		Outcom		
		duration: 3	Rounded sole,	orthoses		in PPP at	
	Control	Control	soft cushioned	\ A / ! + + ! - +	es	lesser toes	
	s (44%)	Control	heel	Within	assessed	(p=0.008),	
		Age: 57(11)		group	Plantar	2-5MTP	
		Median		Participant's	pressure	(p<0.001)	
		Disease		own	(PPP)	and	
		duration: 3		footwear	Tempora	midfoot	
					l spatial	(p=0.003)	
					(walking	in the	
					velocity,	footwear	
					stride	interventi	
					length,	on group	
					cadence,	compared	
					stance	to control	
					phase %)	group.	
						Significant	
						reduction	
						(p=0.015)	
						in stance	
						phase	
						percentag	
						e in	
						footwear	
						interventi	
						on group.	
						Within	
						group	
						measures	
						Significant	
						reduction	
						in PPP at	
						1MTP	
						(p=0.002),	
						2-5MTPs	
						(p<0.001)	
						and heel	
						(p<0.001)	
						in	
						footwear	
						interventi	
						on group.	
						Significant	
						reduction	
						in cadence	
						(p=0.015)	
						and stance	
						and stance	1

phase percentag e (p=0.021).	ACCEPTED MANUSCRIPT						
						percentag e	

Accepted manuscript